South Dakota Investment Council cut its stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 7.0% during the 3rd quarter, Holdings Channel.com reports. The firm owned 38,957 shares of the medical instruments supplier’s stock after selling 2,936 shares during the period. South Dakota Investment Council’s holdings in Becton, Dickinson and Company were worth $6,973,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently modified their holdings of the company. Maryland Capital Advisors Inc. boosted its holdings in shares of Becton, Dickinson and Company by 13,900.0% during the third quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 139 shares during the period. Meeder Asset Management Inc. increased its stake in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares during the period. Bell Investment Advisors Inc acquired a new stake in Becton, Dickinson and Company during the 2nd quarter worth approximately $29,000. Kelleher Financial Advisors bought a new stake in Becton, Dickinson and Company in the 2nd quarter valued at $30,000. Finally, Trifecta Capital Advisors LLC increased its position in Becton, Dickinson and Company by 59.0% during the 3rd quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 62 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on the stock. Zacks Research raised shares of Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 21st. Wells Fargo & Company lifted their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. JPMorgan Chase & Co. lifted their price target on Becton, Dickinson and Company from $170.00 to $202.00 and gave the company a “neutral” rating in a research note on Friday, November 6th. Weiss Ratings raised shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, November 4th. Finally, Wolfe Research started coverage on Becton, Dickinson and Company in a research note on Tuesday, October 20th. They issued an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $197.47.
Check Out Our Latest Report on Becton, Dickinson and Company
Becton, Dickinson and Company Trading Up 0.3%
Shares of NYSE BDX opened at $215.97 on Thursday. The firm has a 50 day moving average price of $192.98 and a two-hundred day moving average price of $170.76. The stock has a market cap of $59.51 billion, a P/E ratio of 16.33, a price-to-earnings-growth ratio of 3.61 and a beta of 0.22. Becton, Dickinson and Company has a 52-week low of $140.11 and a 52-week high of $220.36. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.54 and a current ratio of 0.87.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 EPS for the quarter, topping analysts’ consensus estimates of $4.07 by $0.08. Becton, Dickinson and Company had a net margin of 5.66% and a return on equity of 14.90%. The company had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.11 billion. During the same quarter in the previous year, the business earned $3.96 earnings per share. Becton, Dickinson and Company’s revenue was up 5.4% compared to the same quarter last year. As a group, equities analysts forecast that Becton, Dickinson and Company will post 13.21 EPS for the current year.
Becton, Dickinson and Company Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Investors of record on Thursday, December 10th will be given a dividend of $1.06 per share. The ex-dividend date of this dividend is Thursday, December 10th. This represents a $4.24 annualized dividend and a yield of 2.0%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. Becton, Dickinson and Company’s dividend payout ratio is 101.45%.
Becton, Dickinson and Company announced that its board has authorized a share repurchase plan on Thursday, November 5th that permits the company to repurchase 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to repurchase up to 3.6% of its stock through open market purchases. Share buyback plans are generally an indication that the company’s management believes its shares are undervalued.
Insider Activity
In other news, EVP Michael Feld sold 165 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,993 shares of the firm’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $210.00, for a total value of $628,530.00. Following the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at $23,134,230. This trade represents a 2.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 3,310 shares of company stock worth $688,650 over the last ninety days. Company insiders own 0.40% of the company’s stock.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.
Read More
- Five stocks we like better than Becton, Dickinson and Company
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
